AU2004256000B2 - Pyrrole-2, 5-dithione derivatives as liver X receptor modulators - Google Patents

Pyrrole-2, 5-dithione derivatives as liver X receptor modulators Download PDF

Info

Publication number
AU2004256000B2
AU2004256000B2 AU2004256000A AU2004256000A AU2004256000B2 AU 2004256000 B2 AU2004256000 B2 AU 2004256000B2 AU 2004256000 A AU2004256000 A AU 2004256000A AU 2004256000 A AU2004256000 A AU 2004256000A AU 2004256000 B2 AU2004256000 B2 AU 2004256000B2
Authority
AU
Australia
Prior art keywords
phenyl
treatment
solvate
compound according
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004256000A
Other languages
English (en)
Other versions
AU2004256000A1 (en
Inventor
Patrik Holm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2004256000A1 publication Critical patent/AU2004256000A1/en
Application granted granted Critical
Publication of AU2004256000B2 publication Critical patent/AU2004256000B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
AU2004256000A 2003-07-11 2004-07-08 Pyrrole-2, 5-dithione derivatives as liver X receptor modulators Ceased AU2004256000B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0316237.7 2003-07-11
GBGB0316237.7A GB0316237D0 (en) 2003-07-11 2003-07-11 Therapeutic agents
PCT/SE2004/001115 WO2005005416A1 (en) 2003-07-11 2004-07-08 Pyrrole-2, 5-dithione derivatives as liver x receptor modulators

Publications (2)

Publication Number Publication Date
AU2004256000A1 AU2004256000A1 (en) 2005-01-20
AU2004256000B2 true AU2004256000B2 (en) 2007-07-26

Family

ID=27741986

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004256000A Ceased AU2004256000B2 (en) 2003-07-11 2004-07-08 Pyrrole-2, 5-dithione derivatives as liver X receptor modulators

Country Status (25)

Country Link
US (1) US20060189663A1 (enExample)
EP (1) EP1646625B1 (enExample)
JP (1) JP2007521313A (enExample)
KR (1) KR20060034284A (enExample)
CN (1) CN100478340C (enExample)
AR (1) AR045720A1 (enExample)
AT (1) ATE399776T1 (enExample)
AU (1) AU2004256000B2 (enExample)
BR (1) BRPI0412479A (enExample)
CA (1) CA2532068A1 (enExample)
CO (1) CO5640134A2 (enExample)
DE (1) DE602004014772D1 (enExample)
ES (1) ES2308205T3 (enExample)
GB (1) GB0316237D0 (enExample)
IL (1) IL172759A0 (enExample)
IS (1) IS8291A (enExample)
MX (1) MXPA06000447A (enExample)
NO (1) NO20060080L (enExample)
RU (1) RU2006102129A (enExample)
SA (1) SA04250203B1 (enExample)
TW (1) TW200507836A (enExample)
UA (1) UA82108C2 (enExample)
UY (1) UY28407A1 (enExample)
WO (1) WO2005005416A1 (enExample)
ZA (1) ZA200600229B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
SE0500058D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 5
RU2007130152A (ru) 2005-01-10 2009-02-20 Астразенека Аб (Se) Производные 1, 1-диоксидов изотиазол-3(2h)-онов в качестве модуляторов печеночных х-рецепторов
EP1907564B1 (en) * 2005-06-28 2013-10-23 Daiichi Sankyo Company, Limited Lxr ligand testing method
KR101475088B1 (ko) 2006-08-21 2014-12-23 제넨테크, 인크. 아자-벤조티오페닐 화합물 및 사용 방법
US10004703B2 (en) 2006-10-12 2018-06-26 Biogen Chesapeake Llc Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels
WO2008046014A1 (en) * 2006-10-12 2008-04-17 Remedy Pharmaceuticals, Inc. Treatment of alzheimer's disease using compounds that reduce the activity of non-selective ca++- activated atp-sensitive cation channels regulated by sur1 receptors
US20100143270A1 (en) * 2007-02-21 2010-06-10 University Of Louisville Research Foubdation Therapeutic cotinine compositions
PL2868315T3 (pl) * 2007-12-04 2018-06-29 Biogen Chesapeake Llc Udoskonalone preparaty i sposoby liofilizacji oraz uzyskiwane liofilizaty
US20110034560A1 (en) * 2008-01-29 2011-02-10 Sven Jacobson Liquid formulations of compounds active at sulfonylurea receptors
JP5615274B2 (ja) 2008-07-01 2014-10-29 ジェネンテック， インコーポレイテッド Ｍｅｋキナーゼインヒビターとしてのイソインドロン誘導体及びその使用方法
US8841462B2 (en) 2008-07-01 2014-09-23 Robert A. Heald Bicyclic heterocycles as MEK kinase inhibitors
AU2011299703A1 (en) 2010-09-07 2013-04-11 Snu R&Db Foundation Sesterterpene compounds and use thereof
AU2015204572B2 (en) 2014-01-10 2020-07-30 Inspirna, Inc. LXR agonists and uses thereof
JP7025022B2 (ja) 2016-01-11 2022-02-24 ザ ロックフェラー ユニバーシティー 骨髄系由来抑制細胞関連障害の治療のための方法
AU2018373028A1 (en) 2017-11-21 2020-04-30 Inspirna, Inc. Polymorphs and uses thereof
KR200492570Y1 (ko) 2018-12-04 2020-11-05 박규환 조립식 계단장치를 위한 발판
PL4073025T3 (pl) 2019-12-13 2024-09-16 Inspirna, Inc. Sole metali i ich zastosowania

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69922526T2 (de) * 1998-10-08 2005-06-02 Smithkline Beecham Plc, Brentford 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)
JP2004500332A (ja) * 1999-07-08 2004-01-08 テュラリク　インコーポレイテッド Ｈｄｌコレステロール値を上昇させる組成物および方法

Also Published As

Publication number Publication date
TW200507836A (en) 2005-03-01
JP2007521313A (ja) 2007-08-02
KR20060034284A (ko) 2006-04-21
IS8291A (is) 2006-02-09
EP1646625B1 (en) 2008-07-02
MXPA06000447A (es) 2006-04-07
AR045720A1 (es) 2005-11-09
ZA200600229B (en) 2007-04-25
RU2006102129A (ru) 2006-08-27
AU2004256000A1 (en) 2005-01-20
US20060189663A1 (en) 2006-08-24
CA2532068A1 (en) 2005-01-20
SA04250203B1 (ar) 2008-02-25
WO2005005416A1 (en) 2005-01-20
GB0316237D0 (en) 2003-08-13
HK1088318A1 (en) 2006-11-03
IL172759A0 (en) 2006-04-10
NO20060080L (no) 2006-02-08
CN100478340C (zh) 2009-04-15
DE602004014772D1 (de) 2008-08-14
ATE399776T1 (de) 2008-07-15
CN1820003A (zh) 2006-08-16
UY28407A1 (es) 2005-02-28
UA82108C2 (uk) 2008-03-11
ES2308205T3 (es) 2008-12-01
EP1646625A1 (en) 2006-04-19
BRPI0412479A (pt) 2006-09-19
CO5640134A2 (es) 2006-05-31

Similar Documents

Publication Publication Date Title
AU2004256000B2 (en) Pyrrole-2, 5-dithione derivatives as liver X receptor modulators
US7432288B2 (en) Pyrrole-2,5-dione derivatives as Liver X receptor modulators
US7960380B2 (en) Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators
US20080255207A1 (en) 5-Thioxo-1,5-Dihydro-2H-Pyrrol-2-One Derivatives As Liver X Receptor Modulators
US7582629B2 (en) Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators
US20080125396A1 (en) Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides as Liver X Receptor Modulators
US20080319017A2 (en) Non-Anilinic Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides As Liver X Receptor Modulators
HK1088318B (en) Pyrrole-2, 5-dithione derivatives as liver x receptor modulators
HK1088320B (en) Pyrrole-2, 5-dione derivatives as liver x receptor modulators
CN101098861A (zh) 用作肝x受体调节剂的异噻唑-3（2h）-硫酮1,1-二氧化物的苯胺衍生物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired